Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
about
N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunitiesN-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of actionHomocysteine and cognitive impairment; a case series in a General Practice settingThe Role of Oxidative Stress in Neurodegenerative DiseasesCognitive remission: a novel objective for the treatment of major depression?Dysregulation of glutathione homeostasis in neurodegenerative diseasesThinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signalingEmerging pharmacotherapy for cancer patients with cognitive dysfunctionPreventing Alzheimer's disease by means of natural selectionGlutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrainFormulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the diseaseInflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine.A combination cocktail improves spatial attention in a canine model of human aging and Alzheimer's disease.Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines.Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing miceRedox neurology: visions of an emerging subspecialty.Neocortex and allocortex respond differentially to cellular stress in vitro and aging in vivoModification of brain aging and neurodegenerative disorders by genes, diet, and behavior.Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals.Preventing Alzheimer's disease : separating fact from fiction.Antioxidants as treatment for neurodegenerative disorders.Cognitive enhancers for facilitating drug cue extinction: insights from animal models.Alzheimer vaccine: amyloid-beta on trial.Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications.Clinically tested drugs for Alzheimer's disease.N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiencyOxidative stress and aberrant signaling in aging and cognitive decline.N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms.Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivoCognitive dysfunction with aging and the role of inflammationFree radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models.Efficacy of N-acetylcysteine in phenotypic suppression of mouse models of Niemann-Pick disease, type C1.Antioxidants in central nervous system diseases: preclinical promise and translational challenges.An increased need for dietary cysteine in support of glutathione synthesis may underlie the increased risk for mortality associated with low protein intake in the elderlyN-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases.Activated astrocytes: a therapeutic target in Alzheimer's disease?Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats.Adaptation and sensitization to proteotoxic stress.Elevation of glutathione as a therapeutic strategy in Alzheimer disease.Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants.
P2860
Q24568289-7AECDCC5-B66E-4145-B32E-62C288D01A32Q24615952-DBF53C8E-F63D-418D-8762-E74CAB5E7744Q25257672-7C4D4549-0BDC-447E-844A-D92D64A36229Q26771758-74750484-6FDC-4325-9508-4897E89CFD48Q26775386-D7328E49-2BC6-409D-B2FD-B7E7FC7823D3Q26822726-DF65A722-0F8A-48F3-9F12-2D08769EC9C6Q26864995-F12FEE8F-A672-4EBB-AD19-CD84A8764998Q27026729-4058DAE2-FDD6-4B67-9316-3DF15CC12037Q28088701-AD0C61AD-6509-4147-A6D7-DD24BE3E623DQ28279190-C740DE2A-D204-43BC-B46E-947ADCC4ED44Q28748304-4AA62C61-E4FB-4ECE-9110-7F52114387E4Q30524688-BAFE1455-8026-46C3-BB27-954F5B6E19A0Q33552777-01F64D7E-4E12-4946-8CC7-1CBE7FEDDCB5Q33575000-47138962-6DE3-4CF6-812A-1297075CE558Q33680232-BC37ADE3-3486-4866-B766-AF2CC7C008A3Q33977753-016A4CD4-F126-4C61-B552-B782F70ED280Q34639246-874BDDF0-B726-4B64-87D5-8E142AE98115Q34711201-24E710B7-578F-4F20-9411-9E666012FDC4Q34803558-A485729C-B1B8-479E-BAA8-E07D855BF283Q34847609-C496267F-6AE4-48A8-8EE5-83B9BC10076EQ34974866-CF5A0E17-8658-40E3-8F70-E669BC24B4ECQ35043180-A11377E5-3061-4A76-9CFB-EC38012CD121Q35069720-19FF727C-DA45-4903-B8F8-D4F25ECEBAEBQ35148462-9C2F88C1-A44C-4801-B4BF-75F7BC774E10Q35164747-16F7C8C3-5A23-4862-B823-52EC78D71702Q35965704-741CA186-9821-4F44-8CC8-860BB717BDE2Q35987295-20BF995A-7096-4A98-BC01-26F6223CA243Q36133400-7CD388A6-F807-4174-8936-1AD22D786CF8Q36271462-75EA85DF-3DF8-4B47-B835-E6827E165580Q36443732-A2EFC098-4553-447E-8D29-022ED903873BQ36761675-BCD4012B-0D0F-4584-B3CB-40B286EDC562Q37078859-288B858E-D6FC-4081-BDD8-5A7803E79B18Q37159979-4BABE2E8-4F3F-49D9-93E6-49ACAAF3C729Q37219282-C97D430D-901B-4D14-9FBE-0F4840E2D7E5Q37603362-0A5D556A-985E-4BF0-AF70-8FD737ADADC6Q37630535-1C300152-CB73-4402-93D7-69C5A9CD122BQ37641278-23D123F3-D640-4310-8B9E-648FBEE6C7B9Q37651678-ED8EE28D-3B52-4F8B-9C1C-72CF6F643206Q37947939-6FA2B5BD-FE4C-4100-AC8E-8389278B0159Q38253060-725EC847-07D2-4AF1-9B9F-ED8F4B271160
P2860
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
@en
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
@nl
type
label
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
@en
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
@nl
prefLabel
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
@en
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
@nl
P2093
P356
P1433
P1476
Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease.
@en
P2093
P304
P356
10.1212/WNL.57.8.1515
P407
P577
2001-10-01T00:00:00Z